Phuturdex › Diseases › Amyotrophic lateral sclerosis
Drugs in development · updated 30 October 2026
Amyotrophic lateral sclerosis: drugs in development
As of 30 October 2026 there are 82 active clinical trials (recruiting or ongoing, phases I–III) on 79 drugs for amyotrophic lateral sclerosis. 60 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MasitinibMasitinib AB Science®, Alsitek® | III | 2 | NCT07174492 |
| NUZ-001 | II–III | 2 | NCT04297683 |
| PridopidineNurzigma® | II–III | 2 | NCT04297683 |
| Acetyl-l-carnitine | II–III | 1 | NCT06126315 |
| COYA 302 | II–III | 1 | NCT07161999 |
| DNL343 | II–III | 1 | NCT04297683 |
| FosigotifatorABBV-CLS-7262 | II–III | 1 | NCT04297683 |
| GalunisertibLY2157299 | II–III | 1 | NCT07321860 |
| IbudilastMN-166 | II–III | 1 | NCT04057898 |
| ION363 | III | 1 | NCT04768972 |
| Nerve Growth Factor | II–III | 1 | NCT06391645 |
| RAPA-501 | II–III | 1 | NCT04220190 |
| Tazbentetol | II–III | 1 | NCT07325591 |
| Verdiperstat | II–III | 1 | NCT04297683 |
| NL-CHCHD-001 | I–II | 4 | NCT06392126 |
| FHND1002 | II | 2 | NCT07138014 |
| PsilocybinPsilocybine | II | 2 | NCT06782724 |
| SNUG01 | I–II | 2 | NCT07169175 |
| 18F-OP-801 | I–II | 1 | NCT05395624 |
| ALT001 | II | 1 | NCT07833618 |
| AMT-162 | I–II | 1 | NCT06100276 |
| BIIB147 | I–II | 1 | NCT07855211 |
| Dazucorilant | II | 1 | NCT05407324 |
| Fasudil | II | 1 | NCT05218668 |
| Foralumab Nasal | II | 1 | NCT07688239 |
| Kamlanoflast | I–II | 1 | NCT07396818 |
| LTX-002 | I–II | 1 | NCT07660614 |
| MTP-101C | I–II | 1 | NCT07017946 |
| NB-4746 | I–II | 1 | NCT07369076 |
| NL-TARDB-002 | I–II | 1 | NCT07703462 |
| NL-TARDB-006 | I–II | 1 | NCT07743268 |
| NX210c | II | 1 | NCT06365216 |
| PLL001 | I–II | 1 | NCT06513546 |
| RE104 for Injection | II | 1 | NCT07002034 |
| Tideglusib | II | 1 | NCT05105958 |
| TP04HN106 | I–II | 1 | NCT06726577 |
| TRCN-1023 | I–II | 1 | NCT07674667 |
| Usnoflast | II | 1 | NCT07023835 |
| VHB937 | II | 1 | NCT06643481 |
| VTx-002 | I–II | 1 | NCT07287397 |
Sorted by most advanced phase and number of active trials. Showing 40 of 60 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| RiluzoleExservan®, Tiglutik Kit® | III | 6 | NCT07174492 |
| AmantadineGocovri, Osmolex Er® | II–III | 1 | NCT04302870 |
| MemantineNamenda, Memantine Mylan® | II–III | 1 | NCT04302870 |
| NerandomilastBI 1015550, Jascayd® | II–III | 1 | NCT07321860 |
| TacrolimusEnvarsus XR, Prograf® | II–III | 1 | NCT04302870 |
| TrazodoneRaldesy®, Oleptro® | II–III | 1 | NCT04302870 |
| ZilucoplanZilbrysq® | II–III | 1 | NCT04297683 |
| ColchicineColchicin, Lodoco® | II | 1 | NCT07813858 |
| Cromolyn SodiumSodium Cromoglicate, Cromoglycate | II | 1 | NCT07142291 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 1 | NCT07834450 |
| DarifenacinEnablex®, Emselex® | II | 1 | NCT06249867 |
| MetforminRiomet Er®, Glumetza® | II | 1 | NCT04220021 |
| N-AcetylcysteineAcetylcysteine, Acetadote | I–II | 1 | NCT07414212 |
| RanolazineAspruzyo Sprinkle®, Ranexa® | II | 1 | NCT06527222 |
| TofersenQalsody® | II | 1 | NCT07294144 |
Sorted by most advanced phase and number of active trials. Showing 15 of 19 drugs.
All 79 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Central nervous system disease 38 drugs
- Metabolic disease 30 drugs
- Nutritional and metabolic diseases 5 drugs
- Spinal cord disease 6 drugs
- Proteostasis Deficiencies 7 drugs
- Neurodegenerative Diseases 25 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000690 “Amyotrophic Lateral Sclerosis”. Prevalence: Orphanet.